Investor Alert for NASDAQ: TNDM — Rosen Law Firm Begins Securities Investigation

NEW YORK, Jan. 17, 2026 — Rosen Law Firm, a global law practice specializing in investor rights and securities litigation, has announced that it is continuing to investigate potential legal claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). The investigation relates to allegations that the company may have provided materially misleading information to the investing public, potentially violating federal securities laws.

Overview of the Securities Investigation

The Rosen Law Firm’s inquiry focuses on whether Tandem Diabetes Care misrepresented or failed to disclose important business information to its shareholders and potential investors. According to legal counsel, this conduct may have impacted the company’s stock price, resulting in financial losses for those who bought or held TNDM securities during the relevant period.

If you purchased or acquired shares of Tandem Diabetes Care securities, you may be entitled to recover losses without paying any upfront fees or costs, as the firm works on a contingency fee basis. A class action lawsuit is being prepared to seek compensation for affected investors.

How to Participate in the Potential Class Action

Shareholders who believe they have experienced losses due to alleged misleading statements by Tandem Diabetes Care are encouraged to submit their information and review their rights. To join the prospective class action:

• Visit the submission form provided by Rosen Law Firm at rosenlegal.com/submit-form/?case_id=19024.
• Call the firm toll-free at 866-767-3653.
• Email [email protected] for more information.

No out-of-pocket costs are required for qualified investors to participate.

Background: Tandem’s Press Release and Stock Impact

The investigation stems from a press release issued by Tandem Diabetes Care on August 7, 2025, before the stock market opened. In that announcement, the company disclosed a “Voluntary Medical Device Correction” affecting certain t:slim X2 insulin pumps due to a speaker-related issue that could lead to an interruption in insulin delivery.

Following this disclosure, Tandem’s share price fell sharply by almost 20% on the same trading day, reflecting an adverse market reaction to the information. This significant decline in value is a key component of the basis for the securities claims being investigated.

Why Select Rosen Law Firm

The Rosen Law Firm emphasizes that investors should choose experienced legal counsel with a specific track record in securities class actions and shareholder litigation. The firm highlights their history of achieving notable settlements for investors, including major recoveries and high rankings by securities litigation monitoring services.

Ranked among the top firms for securities class action settlements and recognized in legal industry rankings, Rosen Law Firm points to its past results—such as substantial monetary recoveries and accolades for its founding and senior partners—as reasons why investors may consider their representation.

Investor Considerations and Next Steps

Investors should consider whether they acquired Nantem Diabetes Care securities during the relevant period and may have experienced financial losses tied to the company’s disclosures. Those interested in further exploring their rights are invited to contact Rosen Law Firm for additional details and to take part in the class action process.

It’s important to note that past results in legal cases do not guarantee similar outcomes for new claims, and interested parties should consult qualified counsel before making investment or legal decisions.

#TNDM #TandemDiabetesCare #SecuritiesClassAction #InvestorRights #SlimScan #GrowthStocks #CANSLIM